Results 201 to 210 of about 356,633 (356)

Dysregulation of HOXA genes in acute myeloid leukemia and targeted therapy. [PDF]

NPJ Precis Oncol
Huang W, Zhang F, Zhang Z, Wang Q, Chen S.   +4 more
europepmc   +1 more source

[Clinical observation of 12 patients with refractory/relapsed acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation containing cladribine regimen].

, 2019
Hao Ai, Yuewen Fu, Y Q Wang, Xudong Wei, Yong-Wen Song   +4 more
openalex   +2 more sources

Tumor‐infiltrating B cells participate in shaping the immunosuppressive microenvironment in solid tumors

International Journal of Cancer, EarlyView.
Abstract Tumor‐infiltrating B cells (TIBs) exhibit dual roles in the tumor microenvironment (TME) of solid tumors. While they can enhance anti‐tumor immunity through antibody production and immune activation, certain subsets—such as regulatory B cells (Bregs) and immunosuppressive plasma cells—contribute to immune evasion by secreting inhibitory ...
Zhitong Li, Ziyang Shen, Yuxiang Sun, Pengcheng Zhu, Tongyan Liu, Rong Yin   +5 more
wiley   +1 more source

Exploring Pattern of Relapse in Pediatric Patients with Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Undergoing Stem Cell Transplant Using Machine Learning Methods [PDF]

David C. Shyr, Bing Zhang, Gopin Saini, Simon Brewer   +3 more
openalex   +1 more source

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

International Journal of Cancer, EarlyView.
What's New? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman, Niven Mehra, Laurien J. Zeverijn, Birgit S. Geurts, Karlijn Verkerk, Soemeya F. Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Addy C. M. van de Luijtgaarden, Theo van Voorthuizen, Tineke E. Buffart, Hans Gelderblom, Emile E. Voest, Henk M. W. Verheul   +15 more
wiley   +1 more source

Schlafen 12 Modulation and Targeting in Acute Myeloid Leukemia. [PDF]

Cancer Res Commun
Guillen Magaña JN, Zannikou M, Baran A, Small S, Schieber M, Schipma MJ, Bartom ET, Kocherginsky M, Saleiro D, Beauchamp EM, Eckerdt F, Platanias LC.   +11 more
europepmc   +1 more source

Homoharringtonine suppresses acute myeloid leukemia progression by orchestrating EWSR1 phase separation in an m6A‐YTHDF2‐dependent mechanism

iMeta, EarlyView.
Homoharringtonine (HHT), a clinically approved anti‐leukemic drug, directly binds the RNA‐binding protein EWSR1. HHT induces an allosteric conformational switch in the RNA recognition motif of EWSR1, driving self‐association and liquid–liquid phase separation (LLPS). The resulting condensates act as regulatory hubs that sequester the m6A reader YTHDF2,
Ting‐Ting Liu, Li‐Ting Chen, Xu‐Ying Pei, Shao‐Nan Hu, Fang‐Fang Zhuo, Ze‐Kun Chen, Yang Liu, Jing‐Kang Wang, Ji‐Chao Zhang, Qi Cao, Ling Li, Jing Wang, Tian‐Tian Wei, Bo Han, Peng‐Fei Tu, Xiang‐Yu Zhao, Ruidong Xue, Ke‐Wu Zeng   +17 more
wiley   +1 more source

TIM-3 Promotes Proliferation of Acute Myeloid Leukemia Blasts. [PDF]

Biomedicines
Shi ZY, Sun K, Li ZY, Xie DH, Qin YZ.
europepmc   +1 more source

Inhibition of Enhancer of Zeste Homolog 2 Induces Blast Differentiation, Impairs Engraftment and Prolongs Survival in Murine Models of Acute Myeloid Leukemia [PDF]

Sydney Fobare, Ola A. Elgamal, Mark Wunderlich, Emily Stahl, Abeera Mehmood, Casie Furby, James R. Lerma, Thomas M. Sesterhenn, Jianmin Pan, Jayesh Rai, Megan Johnstone, Amina Abdul‐Aziz, Mariah L. Johnson, N. Shesh, John C. Byrd, Erin Hertlein   +15 more
openalex   +1 more source

Genome‐wide CRISPR screen reveals an uncharacterized spliceosome regulator as new candidate immunotherapy target

iMeta, EarlyView.
This study identifies the uncharacterized gene C9ORF50 as a novel regulator of immune evasion. Functioning as an intrinsically disordered protein, C9ORF50 drives liquid‐liquid phase separation to facilitate spliceosome assembly and maintain RNA splicing fidelity.
Tong Shao, Chuanyang Liu, Jingyu Kuang, Sisi Xie, Ying Qu, Yingying Li, Lulu Zhang, Fangzhou Liu, Yanhua Qi, Tao Hou, Ming Li, Sujuan Zhang, Yu Liu, Zhixiang Yuan, Jiali Liu, Yanming Hu, Jingyang Wang, Chenghu Song, Shaowei Zhang, Lingyun Zhu, Jianzhong Shao, Aifu Lin, Wenjun Mao, Guangchuan Wang, Lvyun Zhu   +24 more
wiley   +1 more source